Eden Research Share Price (EDEN)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.025 -0.36% 6.85 164,368 15:42:43
Bid Price Offer Price High Price Low Price Open Price
6.70 7.00 6.875 6.85 6.875
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.05 -1.48 -0.54 26
Last Trade Time Trade Type Trade Size Trade Price Currency
15:42:11 O 15,000 6.75 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Eden Research (EDEN) Latest News

Eden Research News

Date Time Source Headline
05/8/202019:16ALNCUK TRADING UPDATE SUMMARY: Regional REIT Valuation Dips In First Half
05/8/202007:38ALNCFAlliance News Flash Headline
05/8/202007:00UKREGEden Research plc New authorisation for Cedroz(TM) in Greece
10/7/202007:00UKREGEden Research plc Appointment of Global Head of Biology and Dev
01/7/202007:00RNSNONEden Research plc New office and laboratory in Oxfordshire
25/6/202014:53ALNCIN BRIEF: Eden Research Gets Two Patents For Sustaine Technology In US
25/6/202007:00UKREGEden Research plc Patents granted in the United States
24/6/202012:20UKREGEden Research plc Result of AGM
29/5/202007:58UKREGEden Research plc Issuing of Annual Report & Notice of AGM
27/5/202007:00UKREGEden Research plc Update on Bayer Animal Health Agreement
More Eden Research News
Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
06/8/202010:57Eden Research; novel encapsulation and delivery technologies1,070
05/8/202012:44Eden Research7,987
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3
18/5/201202:24Eden Research6

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-06 14:42:126.7515,0001,012.50O
2020-08-06 14:05:216.7553,0883,583.44O
2020-08-06 13:03:436.758,275558.77O
2020-08-06 12:31:446.755,000337.63O
2020-08-06 11:43:156.7510,000675.25O
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

DateSubject
06/8/2020
09:20		Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 6.88p.
Eden Research Plc has a 4 week average price of 6.75p and a 12 week average price of 6.25p.
The 1 year high share price is 10.75p while the 1 year low share price is currently 4.65p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 57,373 shares. The market capitalisation of Eden Research Plc is £26,053,305.69.
Read Full Thread
Reply
15/6/2020
14:03		investingisatrickygame: super (and others) In the November 2015 Shore Capital Broker report, page 18 it stated the following ""Bayer acquires AgraQuest (August 2012): Bayer acquired AgraQuest for €340m plus milestone payments. AgraQuest is an innovative provider of biological-based pest management and plant health products with a portfolio of existing products and several under development. We believe AgraQuest had revenue of $7m in 2012 so it is probably the most comparable company to Eden." It appears to me (without further investigation) that AgraQuest may have been very similar to Eden in its commercial timeline (accepting Eden hasn't yet hit $7million per annum). Today, you get 1.12 dollars to a Euro meaning Bayer in today's money paid circa $382 million or 55 times annual income. So I am thinking that Eden has a portfolio of pest management products and a raft of granted and pending patents (110 according to the latest 2019 AGM presentation), just like AgraQuest. IF Eden lands the Corteva deal the annual income from that alone of €40 million is 5.7 times that of AgraQuests annual income at the time of the deal Lykele Van Der Broek - Non Executive Chairman, Eden Research Plc "Lykele retired as a Member of the Board of Management of Bayer CropScience, a division of Bayer AG, in 2014, being responsible for the commercialisation of innovative agricultural products and services globally. Prior to this, he held senior international roles including the Head of Bayer CropScience’s BioScience division and President of the Bayer HealthCare Animal Health division." Question - was Lykele involved in the negotiation of that deal? Some who are more investigative than me may wish to prod around. It does appear to me that by the time the Corteva evaluation is completed this year, should that deal go ahead then Eden becomes a takeover target. From 8p and if Eden was taken over, based on the above, the Eden share price could rise to multiples of £'s, quite easily. Added to which we will likely have many Cedroz approvals by then, including the USA. Finally, I assume, none of this takes account of Sustaine. So if Eden can further prove Sustaine through multiple products in their Collaboration and Evaluation Agreement with Sipcam (where we are surely due news one way or the other)and this is part of Eden's overall, £'s seems very likely to me NOTE: I have no idea if AgraQuest had game-changing technology as part of their appeal to Bayer. Surely, a successful Corteva deal as outlined in the recent Eden Placing RNS will deliver a new valuation note on Eden and hopefully a buying frenzy recognising significant upward value and in a vastly undervalued company.
Read Full Thread
Follow
Reply
05/5/2020
10:09		investingisatrickygame: Look at Genedrive again today. 9p on the 29th March to just short of a £3 high this morning. Yes they have now come off a £1, but who wouldn't be taking that profit in 37 days....I would. Look at today's Placing RNS from them, Well structured, chronological and at each point referencing the climb in the share price with each RNS that came along. They're looking to raise development funds at 80p and my guess is that will be a walk in the park. Now look at this statement from the RNS "The Directors believe this share price performance has been driven by increased investor interest in companies with potential diagnostic and therapeutic solutions to the COVID-19 crisis" Full recognition that investor interest (and I'm confident looking at the trade sizes that it is PI's) is driving share price and company value for the "potential solutions" that they have. Investors can see the potential Investors can understand that this is a global opportunity Investors don't even know the potential value of the global proposition because the Company, as far as I can see, hasn't declared the same potential Yet, investors are excited and understand that Genedrive are not doing this for pennies. So my singular point here (understanding that Covid-19 is at the forefront of people's minds) is that the investment community sufficiently understands in broad terms that this is a global proposition to a global problem. I always talk about investors understanding a company's proposition, product, market, potential, value..... I still don't think investors have grasped what Eden is doing, what Eden can and will solve, what value that will bring to Eden, as well as their distributors & farmers. We have what is now a highly understood issue with microplastics which we can play on. Investors and consumers will like that story. We have organic status, both will like this again We have (near) chemical free solutions, so not pesticides in the truest sense, again, investors and consumers will like this story and so will the press We have ground-breaking, game-changing proven technology, definitely something investors will want in on Mr Bayer in Lykele is now at "The Natural Solution" company. Why/What's the story? Investors, consumers, press will all love to hear the why Pesticides are coming off market, driven by Regulators and Eden is only one of a few globally......... Eden has so many terrific platforms on which to deliver its story. No pump and dump, no over egging the position. Simply a strong and qualified execution of the whole story, the problems in play, the solutions that Eden has and the value of those to the Crop Protection market. If Eden played this out and convinced the investor market of what it is delivering and resolving, I feel confident we would see a significant and deserved upward trajectory in Eden's share price too. Illiquidity, 7 pence and £26 million is not where Eden should be right now and investors would agree, as exampled above, if only they truly understood the global Crop Protection issues that Eden is resolving. One final point. Genedrive is providing a Covid-19 test kit. I read in the press yesterday that once you've had the Coronavirus your body DOES develop antibodies and so one assumes that there are only so many tests that one can take for Covid-19. Crop Protection on the other hand happens year, after year, after year, after year......a totally recurring income stream, unlike a Covid-19 test kit. And one more thing In a misunderstood company shareholders ask questions; lots of them to both the company and to the PR firm I suspect that the Genedrive CEO and his PR team have had very few interventions because in a rising price and rising value, individuals take it and feel elated that they have made money. So a rising share price solves many issues, this being just one of them. Private Investors can take Eden's share price to the next level. Arguably, Eden's shares are more tightly held now post Placing. Create the excitement around reality and Eden's share price will rise dramatically.
Read Full Thread
Follow
Reply
20/1/2020
09:36		investingisatrickygame: wan Post #862"some of your rants!" I don't see it that way, but each to their own. I do 'go on' about and aim to back up where possible about 2 things 1) Eden's share price 2) Eden's communications Let's deal with number two In the last 2 years+, Eden has now moved on to its third PR Company. Walbrook, Powerscourt and now Hawthorn. That tells me two things. 1) Eden has an investor image problem. They are not understood, as reflected in the share price. We can example a lack of understanding in the recent challenge from mirandaj to me about Cedroz. Supersonico has also challenged mirandaj and you too have commented on the same. If Eden had communicated sufficiently on the subject, there would in theory, be no misunderstanding and the conversation on this BB would not have evolved. It could of course be that we all have terrible memories and that Eden has communicated clearly. That said, the four of us have debated it. The problem with this poor image is that the BB's, rightly so, become the image of the Company because it is the only place that is holding debate and seeking answers that are not provided by the Company. Therefore, a Company, today, has to take control of its own communications (which Eden chooses not to do) to ensure that that communicate at the deepest level of relevance to shareholders, so that they do understand, so that they can invest with confidence, so that these BB's do not become the image of the Company. Eden in my opinion, has yet to acknowledge this. 2)I know that Powerscourt was only charged with financial PR. So to be fair to Powerscourt, they had no remit to go beyond this and be more expansive about Eden. I believe this was the case with Walbrook too, event though they tried to get Eden to step forward. So we appear to have two consecutive PR firms, tied by Eden's apparent lack of share price ambition through communication to unravel the story and understanding properly for the benefit of the whole investor community. What remit has Hawthorn been given, do they want to follow the situation of their predecessors or are they just happy to receive their monthly fee and follow in the footsteps of the last two? Let us all hope the latter is not true. Personally, I do not think it reflects well on the Company for Eden to have 3 PR companies in such short time. I also do not think it reflects well on the Company to say they have no time to do communications because they area small staff base. To me, that is avoiding the elephant in the room. It is the single most important thing right now having Mevalone on sale in multiple countries, Cedroz going global, the Corteva deal and no doubt other global arrangements to soon follow. They have to get reflective value in the share price and they have to make time. They're possibly giving over a day to the forthcoming High Growth and Innovation day run by Shares Magazine. If so, they can certainly organise their time to deliver film which will be seen by many more people and create a library of news and communications to go back and look upon to cement ones understanding of Eden Research Plc. Share Price I do go on about the share price and this is because I do not think Eden is fairly valued at circa £18 million. If Eden was to come out and say within their communications that they are happy with their current market valuation and it reflects where they are in their corporate journey, so be it....but they don't. It is my opinion therefore that this needs addressing and the share price should be multiples of what it is today. To me, these are not rants, they are constructive opinion which is borne out be today's RNS and the depressing share price of today.
Read Full Thread
Follow
Reply
07/12/2019
12:36		kenmitch: supersonico You’ve hit the nail on the head with your last question. If you are right Eden share price wil rocket! That’s why I still follow it, because you could be right. . BUT those massive gains won’t all come in 1 day. There could well be years where the share continues to rise as sales and profits soar year on year. Eden could even become a FTSE100 Company, and aside from the very start I’ll be in for that exciting ride. But I still can’t see the point of having my money tied up on this dream. I would rather miss the very beginning of the massive share price gains to come and invest again on genuine good news. Eden fans have been dreaming for so many years. It IS still right to dream because the promise of eventual success is still there, but there’s also the risk of it staying a dream for a lot longer.
Read Full Thread
Follow
Reply
14/11/2019
08:30		investingisatrickygame: Morning wan, All very nice 'window dressing', but still, no one is looking in the window. The share price is further depressed and shows no intent to move upwards. I think we all understand in broad terms that Eden has good 'tech' and that being highly recommended reflects this. But, Eden management is in the business of operational execution to deliver success and this as a plc is most usually reflected in the share price. The share price shows no recognition of achievement whatsoever, does it?! Is Eden fairly valued at £16 million? Does that price in a global sales and distribution agreement with Eastman and the associated geographies for Sipcam with Mevalone? Does it price a fraction of the opportunity and possibility of Sustaine? Management remuneration continues to be high and their options price in a fraction of the opportunity and possibilities in the future for success. Remuneration packages at Eden and the Eden share price are not aligned, nor are the efforts towards the latter. I would like to see Eden fully recognise this and acknowledge the same and put some serious effort into turning the situation around. Trying and failing is one thing, but not really trying on the share price is another thing altogether. When you have such good remuneration packages you can afford for the share price to float around and underperform, but that may not be the case with your fellow shareholders, especially when they have invested in the promise land and been here for so long. It feels appropriate to me that Eden finally takes stock of this and apportions some of their working time to 'fixing' the share price for the benefit of all.
Read Full Thread
Follow
Reply
22/9/2019
11:22		investingisatrickygame: Eden in summary R & D product X how many years Field trials X two seasons/years Regulatory approval X one year or up to Product sales and conversion/adoption X 2 years plus to gain trust and penetrate the market Possibly 5 years from field trials to meaningful revenue (when a product is not seasonally affected, like Mevalone, otherwise longer). Eden's share price 26p to 9p in 5 years when Eden HAS successfully gone through the above, so -60% We are told G3Y is entering the end (I believe) of season 2 trials, so maybe another 3 years before any meaningful revenue. Cedroz is known about, is a replacement product for Eastman and so should grab, hopefully, a natural market share. Regulatory approval is not yet secured, so maybe 2-3 years away. Brokers consistently WILL NOT factor in the next 3 years anticipated income for Eden. QUESTIONS What is it that management expects will drive the share price given the above? What is it that shareholders think will drive the share price given the above? Artemis has been a seller for a while as evidenced by the share register. When that overhang is gone, will the price rise a little or will another seller materialise? Even if the sellers are removed and the price rises, what is the first price point for exasperated shareholders to exit? Has Eden and its advisers planned for this? If so how? Who will step in again and mop up the sellers at that point? Eden in my opinion has an ongoing overhang whereby shareholders will sell into any rise that occurs because faith, time and more has them longing to remove themselves from the dire situation of the Eden share price. There are plenty of regulatory environments where share prices fly beforehand. Eden doesn't require huge capital to get of the ground, yet huge capital projects that do, still see there share price flying, knowing that is ahead of them, but because the asset base has risen. Eden excuses around regulatory environments doesn't hold water. It is wrong of them to say so and to say that shareholders don't understand when I'm sure that they do. Eden assets, in part, are its IP. 110 granted and pending patents we are told, but no value seems to be apportioned to these assets. Could that be because of the suggested timelines above? Personally, I feel that Eden makes too many excuses on third parties and process as their excuse for the share price and doesn't put enough emphasis on the forward value of the business and the solutions they deliver to the crop protection market which are much needed. their story is one of excuses and negativity, not one of reasons to invest and positivity. They do not open up the investment communities eyes to what they believe they will deliver. And, their emphasis continues to be institutions when Eden has a declining share price making Eden even less attractive and less able to invest in (Mcap). The resulting effect as we see is no demand for the company's shares, no belief in management as evidenced by the lack of buying and a flight elsewhere to greater visibility, expectation and potential reward.
Read Full Thread
Follow
Reply
13/9/2019
22:50		investingisatrickygame: All of this focus on the future should be focused on the present. We, as shareholders, have been focused on the future for years. For how many more years are we going to say, the trend is from pesticides to biopesticides, when Eden gets in profit, let's wait and see what the interims say, let's wait and see what the full year-end figures are etc, etc, etc. The trend regarding pesticides to biopesticides, consumer opinion and demand and more is not the trend of the share price. Again, 26p in 2014 to 10p in 2019. Totally against the trend. Why is the Eden share price going against such a favourable trend and outlook? Why is management not kicking up a stink about this awkward share price trend? Why is management not adding to the BoD with someone who has an absolute focus on the share price and an ability to move the same? Why has Cenkos not bought one single share since their 'Killing It' report? How do Cenkos sales team on the back of that title encourage buyers when the share price target is just 12p? How does Eden management appear credible to investors given all of the above when they talk about their global ambitions and being just 'one of a few globally' etc, etc. Either management has to do something about the share price or maybe management needs new or/and replacement personnel to deliver the value that is so sadly lacking. These are the discussions investors should be having right now and not the blue sky and general industry discussions that are taking place. The share price reflects complacency and that is not good enough when you are a Plc, listed and with responsibilities to shareholders.
Read Full Thread
Follow
Reply
10/8/2019
19:45		investingisatrickygame: PaulPaolo, post 6698 said "Have you not noticed that Eden is the most reticent of all firms about positives ? On balance, I do prefer this approach to the more showmanlike, untrustworthy (as I see it) CEOs of firms like Sound Energy, PANR, Kod and UKOG, who shout in RNS’s they “are delighted to announce good news” when there often seems to be none that’s real, and whose shares long term seem to turn out to be dogs." AND "Meantime, the poor comms compared to other AIM firms, keeps the shares cheap and I’ve gradually built up a good holding." Firstly, in my opinion, it is not about being "showmanlike", it is about behaving as a listed company should do or not be listed at all. Eden should shout about big news and enthuse and explain the same to encourage inward investment in the share price. If you are not going to do that then don't waste money with Proactive with dull and uninspiring interviews. Eden does have good news, does it not, but it makes very little effort to be truly expansive about its news and in turn convey a value proposition to those watching. So I do not see the comparisons you offer up as valuable when looking at Eden. It is also a mistake to be understated in my opinion and to not aid true and fair value into your share price You seem reasonably happy that communication is poor allowing to keep buying cheap shares. What about all of the long-term investors of say 10 years that are ripping their hair out because of Eden's ongoing inability to deliver true value into today's share price? I doubt they share your delight and rightly so. Let's see what price point Cenkos puts on Eden. I'll bet you it is much higher than Shore Capital and if so, the gap in value will look event bigger and management will look even poorer for that report, as will Eden's other advisers. The whole Eden share price is in my opinion, a disgrace and I know others think the same. I'm losing interest in the story, the application is undeniable, but value is all I seek now because it is value, or lack thereof, that has soured the story and that is something Eden will struggle to get away from.
Read Full Thread
Follow
Reply
11/6/2019
00:33		investingisatrickygame: From Super's post, number 6400 hxxps://www.crophealthnorth.co.uk/wp-content/uploads/2019/03/EdwardsGwynn-CropTec-widescreen.pdf The global market for biopesticides in 2019 is $6 billion From Eden's 2018 AGM presentation "Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation" Eden's market Cap is circa £22 million So which of the other 'few' global players has all the value & the sales? And what are their market caps? And how do they differ from Eden? It appears increasingly strange to me that Eden makes such statements and yet the divide between the statement and Eden's value is like a chasm. These things need better consideration and deeper explanation if people are to buy the Eden share price. In theory, based on Eden's statement and the 2019 market value then Eden should be priced at £'s, not pence. 'Professional' investors in the City have investment rules, will look for the onset of deep profits, dividends & more. Eden has thus far been unable to penetrate this market and Powerscourt have been unsuccessful in inducing that investment into Eden. Private investors don't have those rules, they look to get in early and cheap and they look for high capital growth and which point the 'professionals' step in and invest and the Pi's retreat, happy with their ROI. Eden still needs to address the latter and convince them to buy, something they continually demonstrate a lack of will to do
Read Full Thread
Follow
Reply
30/5/2019
09:42		investingisatrickygame: I know a number of people are really fed up with the ongoing lack of value being reflected in the share price. I certainly am. How long, even in a regulatory framework, can one continue with the mantra that these things take time, especially when we have two commercial products, delivered via Sustaine, with Sustaine (we assume, not unreasonably) having successful trials elsewhere with Agrochemical majors and full confirmations still to come alongside commercial arrangements. Mevalone is now a global product as a result of Sipcam's uptake right's. It is, we are told, being used now as a pre-harvest, 'protector'/'insurer' against the possible later onset of Botrytis and it has post harvest viability too. Exempt from MRL & Generally Regarded As Safe (GRAS), Mevalone is the Natural Solution. From a marketing perspective, Eden and Powerscourt have everything to hand here except organic status. This story can run well either with the support of the press or stand alone using video and distribution partners to place in the right channels for understanding and word-of-mouth. Many people should be talking about Eden to the positive and it should create its own direction of travel. This is before we even address Cedroz which has a bigger impact, plus the awaited new products in bigger markets. You can take a definition from wherever you want, I've taken the easiest to find. "The chief executive officer (CEO)[1] or just chief executive (CE), is the most senior corporate, executive, or administrative officer in charge of managing an organization – especially an independent legal entity such as a company or nonprofit institution. CEOs lead a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (e.g., Crown corporations). The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price, market share, revenues or another element. In the non-profit and government sector, CEOs typically aim at achieving outcomes related to the organization's mission, such as reducing poverty, increasing literacy, etc. In the early 21st century, top executives typically had technical degrees in science, engineering or law.[2]" From above "The CEO of a corporation or company typically reports to the board of directors and is charged with maximizing the value of the entity,[1] which may include maximizing the share price" I have no issue with Sean's online delivery, nor his connections, nor his IP knowledge and background. I have no basis to, I doubt anyone does. However, he is not maximising the share price. It cannot be argued one day Rodney, when so many days have passed with the result of the above products, relationships and technology. And we have a former high ranking employee of Bayer as our Chairman which doesn't on the face of it after 18 months in situ, appear to be delivering anything of value that we as shareholders can measure. That is fair observation. A CEO has to deliver share price value and that has to be on an ongoing basis, trending upwards and in line with business performance + forward prospects, traditionally measured on a three year timeline. Eden has nothing factored in for the latter and much of its business achievement thus far not factored in to today's share price. It is illogical and unrealistic to expect that one moment in time, yet to come, will catapult the share price north and vertical in an instant and correct all share price performance woes to-date. That if it ever happened, would lead to a mass sell out and a decline in the share price as quick as the incline that occurred. The CEO of Eden has to maximise the share price now and this is an ongoing role and responsibility. it isn't to be implemented when you wish to. It is an ongoing process. NDA's, partners et al do not have the power to supress another's share price and it is unthinkable to imagine this can be so. I know the BoD will read this and other posts and I know they will know who wrote this. I have no ill will towards the BoD, but our CEO whoever that may be an any point in time has to do their utmost to ensure that the share price of today and every day reflects the true value of the Company today. If they truly believe our share price and market cap is fair value right now, then do nothing at circa £23 million. If however this is not what they believe and know value to be, then they need to act to move the share price and show their audience true reasons why the share price should be much higher and therefore why people should invest in it today. This 'moan' by many is not going to go away until it is dealt with. Institutions are not and do not buy into Eden at this level. So they truly have no options but to stir up the market and in due course the hoped for institutions might come on board. Is our current CEO going to be the CEO to put value into the share price today based on current achievements or is another going to be brought into the business to deliver that value today, as well as the ongoing process of creating value for the future, the latter of which I am sure Sean is seeking to achieve.
Read Full Thread
Follow
Reply
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200807 04:58:04